Logo

Janssen's Stelara Fails to Show Superiority over AbbVie's Humira in P-IIIb SEAVUE Study for Crohn's Disease- Presented at DDW 2021

Share this

Janssen's Stelara Fails to Show Superiority over AbbVie's Humira in P-IIIb SEAVUE Study for Crohn's Disease- Presented at DDW 2021

Shots:

  • The P-IIIb SEAVUE study involves assessing Stelara(6 mg/kg- IV at baseline- then 90mg- SC- q8w) vs Humira (160/80mg- SC at baseline- then 40mg- SC- q2w) in the treatment of 386 biologic-naïve patients in a ratio (1:1) with mod. to sev. active CD
  • The data demonstrated high rates of clinical remission- corticosteroid-free remission- clinical response- and endoscopic response through 1yr.- although the 1EPs of statistical superiority was not demonstrated
  • Additional abstracts of data are also being presented at DDW- which include safety of Stelara in IBD along with long term data of Stelara in the IM-UNITI study with RWE of the therapy for CD

  Ref: J&J | Image: Janssen

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions